A dialysis authentication and management system comprising at least one dialysis component having at least one authentication component affixed thereon. The dialysis component can be any one of a dialyzer, sorbent cartridge, recharger or any other dialysis component. The authentication component can be selected from the group of a radio-frequency identification marker, a bar code, a one-wire security component, and a wireless authentication component. The authentication system can ensure that all components used are in proper usable condition and/or certified. The system can also manage the recharging of rechargeable components, and optionally manage dialysis therapy.

Embodiments provide methods and apparatus for fabricating blood products, such as platelet-rich plasma, containing elevated concentrations of growth factors such as platelet derived growth factor. The platelet-rich plasma can be autologous, and the concentration of growth factors (e.g., platelet derived growth factor) is elevated relative to other samples isolated from the same subject. The platelet-rich plasma can be used to promote tissue regeneration, including wound healing, joint repair, hair growth, and the like. The compositions can be combined with stem cells and used to treat disorders otherwise treated with stem cells. The growth factors present in the samples can direct the differentiation of the stem cells.

A system, device, and autologous method for treating blood. Blood is extracted from a patient. The blood is tested to determine one or more pathogens and conditions of the blood. One or more catalysts are automatically added into the blood of the patient. The one or more catalysts are activated utilizing the one or more emitters configured to interact with the one or more catalysts in the blood create treated blood. One or more additives are added into the threated blood. The treated blood is reinjected into the patient.

System and method for pathogen inactivation with UV-C light (employed by itself or in addition to filtering out particulates rom the flow of air reaching the user) by delivering, into a lightguide portion of the air inactivation chamber of the system, a dose of ultraviolet radiation sufficient for at least one log reduction level of the pathogen while, at the same time, multiply reflecting the light inside the chamber to increase the irradiance of inactivating light several fold (up to 5×, or even up to 8.6×) as compared to that delivered to the chamber.

Methods and systems for maintaining patient fluid balance during an extracorporeal cell treatment are disclosed. The method includes minimizing the amount of saline or other fluid that is returned to the donor. Saline used during priming of the fluid circuit may be used to increase the volume of the collected cells to arrive at a treatment-ready product with a suitable hematocrit.

Fluid processing assemblies and methods are provided for mononuclear cell collection. Mononuclear cells are separated from red blood cells in a blood separation chamber, with the mononuclear cells and then the red blood cells exiting the chamber via an outlet port. The mononuclear cells and then the red blood cells enter an outlet flow path that is in fluid communication with a mononuclear cell collection container. The outlet flow path includes a visual indicium, which an operator may use to determine the position of the red blood cells within the outlet flow path and when to end mononuclear cell collection by preventing fluid communication between the outlet flow path and the mononuclear cell collection container.

A method and a system for producing a change in a medium. The method places in a vicinity of the medium an energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The energy modulation agent has a normal predominant emission of radiation in a first wavelength range outside of a second wavelength range (WR2) known to produce the change, but under exposure to the applied initiation energy produces the change. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.

An embodiment provides a method for treating a body fluid of a patient with Covid-19, including: removing the body fluid from a patient, wherein the body fluid comprises a Covid-19 targeted pathogenic antigen (TPA); applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with the Covid-19 targeted pathogenic antigen in the body fluid to form an antibody-TPA complex, wherein the antibody comprises a radiofrequency absorption enhancer forming an antibody-radio frequency enhancing moiety-virion complex (ARFVC); removing the ARFVC from the body fluid using a radiofrequency source; and returning the body fluid to the patient. Other aspects are described and claimed.

Provided herein are systems and methods for implementing a modular light device for use in an electronic treatment device according to examples of the disclosure. In one or more examples, the modular light device can be implemented as a stand-alone component that can be swapped in and out of the treatment device. In one or more examples, the light device can include a light source array chamber configured to transmit UV light of a selected wavelength, the light source array chamber including one or more light source arrays and light sensors collectively configured as part of the light device to deliver light to a biological sample.

A system to be used to treat Leukemia, comprises a device to power, control and monitor an ultraviolet radiation as well as to monitor a blood contactless conductivity; and a catheter assembly with an inner dialysis catheter, an ultraviolet radiation source and a differential coil sensor. The system is using wavelengths of ultraviolet radiation to destroy infectious microbes that are in the blood and that are inside circulating tumor cells directly and indirectly as well as to destroy infectious microbes at primary tumor location (bone marrow). This is done without withdrawing the blood out of the body. Furthermore, the system measures a blood conductivity to evaluate the treatment process in a real time during the operation.